Mirum's Volixibat Setback Tests a Bullish Commercial Story

Strong Q2 and FOP launch prep meet an FDA detour in PSC.

MIRM · Earnings Call · 2026-08-05

Strong Commercial Execution Continues

Mirum entered the quarter on a high. Net product sales hit $176M, with Livmarli contributing $129M and bile acid medicines $48M, prompting management to raise full-year guidance to $680–700M. Peter Radovich highlighted the durability of Alagille growth and the emerging adult PFIC opportunity, now estimated at over 2,000 addressable U.S. patients. This commercial strength underpins the company's capacity to invest through potential turbulence.

Volixibat: Breakthrough Designation but a Delayed NDA

The headline was the regulatory interaction for volixibat in PSC. After VISTA met its primary endpoint, the FDA granted breakthrough therapy designation, but at the pre-NDA meeting recommended an additional Phase 3 study. Management pushed back, emphasizing the robustness of the data and noting the breakthrough designation provides a path for iterative discussion.

The FDA recommended conducting a phase 3 study. We believe the VISTA study provides a robust and clear dataset to characterize the use of volixibat in patients with pruritus due to PSC, and is a clinically and statistically highly persuasive study.
Christopher Peetz, Chief Executive Officer · 2026-08-05

The company now targets an NDA submission for the first half of 2027, a slip from the prior second-half-2026 timeline.

Pipeline Catalysts Remain Dense

Despite the PSC delay, the pipeline is full. Volovitug (AZURE-1 readout later this quarter; AZURE-4 in Q4) supports a BLA submission in H1 2027. The EXPAND study for Livmarli in additional cholestatic conditions reads out in Q4, and VANTAGE in PBC remains on track for Q1 2027. The VANTAGE study benefits from earlier FDA feedback and a clear pivotal designation, in contrast to the PSC situation. “So we have direct input for that indication for vantage. So feel like that is on a good course.” — Christopher Peetz, Chief Executive Officer · 2026-08-05 On the commercial side, Zilurgisertib for FOP is approaching its September PDUFA date. “We feel the application is progressing, you know, quite well towards the PDUFA date.” — Peter Radovich, President and Chief Operating Officer · 2026-08-05 Peter Radovich expects a Q4 launch leveraging the existing rare genetics team.

Financial Strength Provides Room to Maneuver

The balance sheet remains a pillar. The company issued $690M in 0% convertible notes due 2032 and settled 75% of its 2029 notes, adding cash and reducing interest expense. Cash and investments at quarter-end were $561M. While the PSC delay raises questions about the timing of volixibat revenues, the increased net product sales guidance and pipeline breadth give management confidence. Total revenue reached $160M in the latest quarter, up 43% year-over-year, reflecting the commercial momentum. However, the company's net income took a large non-cash hit (likely from debt and in-process R&D), underscoring that profitability remains downstream. Management repeatedly stressed that pruritus is an approvable endpoint and that the VISTA dataset is sufficient. As Christopher Peetz noted, “using pruritus is the basis for full approval... we do not expect to have a post approval study in the sense of kind of confirmatory accelerated approval type format.” — Christopher Peetz, Chief Executive Officer · 2026-08-05 This is a critical distinction from an accelerated approval scenario. Investors have reacted cautiously; the stock is down 25% from its July high of $128.57, though it remains up ~1% over the past 90 days. The upcoming months will be dominated by the AZURE-1 readout and the FOP launch, both of which could offset regulatory overhang. Prior quarters have prepared the market for this moment. In May, management highlighted the strength of the volixibat package and the FDA's engagement. “We have had full access to clinical data, to the regulatory correspondence, and the NDA. So we feel quite confident in the profile for zoligosertib and where they are at in the regulatory process.” — Christopher Peetz, Chief Executive Officer · 2026-05-06 And in November, they described the VISTA design as conservative and well-powered. The new wrinkle is the FDA team change, which management believes is driving the recommendation. The VISTA study remains the core evidence, and the breakthrough therapy designation provides a pathway for expedited engagement. Overall, Mirum is in a period of transition: strong commercial execution, a crowded catalyst calendar, and one regulatory curveball. The market's reaction suggests skepticism, but the coming months will test whether the FDA's request is a hurdle or a detour.